Screening Libraries
Cat. | Size | Price | Stock | |
T10145 | 1mg/well * 7 Compounds | Inquiry | In stock | Contact Us |
T10145 | 100uL/well (10mM solution) * 7 Compounds | Inquiry | In stock |
manager@chemfaces.com | |
Tel | (0086)-27-8423-7683 |
Shelf Life | (0086)-27-84254680 |
Manufacturer | Wuhan ChemFaces Biochemical Co., Ltd. |
Container | 96 Well Format Sample |
Storage | Protected from air and light, refrigerate or freeze(2-8 °) |
Shelf Life | 24 months (2-8 °) |
Intended Use | For research use only. Not for human use. Not sell to patients |
1. The products in the ChemFaces screening libraries are all from plants. |
2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research. |
3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools. |
4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity. |
5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution). |
Catalog No. | Information |
CFN99198 | Celastrol Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol is also a novel HSP90 inhibitor, it has anti-proliferative, anti-inflammatory, anti-tumor , antiangiogenesis, and antioxidant activities. Celastrol inhibits Plasmodium falciparum enoyl-acyl carrier protein reductase and inhibits VEGF receptors expression. |
CFN99934 | Alantolactone Alantolactone, an allergenic sesquiterpene lactone, has significant antitumor effects on malignant tumor cells, it can suppress inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-κB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells, and inhibit cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway. |
CFN98107 | Isoalantolactone Isoalantolactone, an apoptosis inducer, possesses multiple biological activities including antifungal, anthelmintic, antimicrobial, anti-inflammatory, antitrypanosomal activities and antiproliferative effects on several cancer cell lines, such as colon, melanoma, ovary, prostate, lung, and leukemia. Isoalantolactone induces apoptosis, may be mediated through caspase-dependent apoptotic pathways, S phase arrest, inhibition of phosphorylation of PI3K/Akt, and downregulation of Bcr/Abl. |
CFN98527 | Icaritin Icaritin, a potent inhibitor of transcription factor SREBPs, which exhibits a variety of biological activities, such as activation of cancer cell apoptosis and inhibition of growth, hormone regulation, protection against beta amyloid-induced neurotoxicity, and promotion of neuronal and cardiac cellular differentiation. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. |
CFN90015 | Dasatinib monohydrate Dasatinib monohydrate is a selective protein tyrosine kinase inhibitor with immunomodulatory properties that abrogates multiple signal transduction pathways in immune cells, it may be used to treat multiple sclerosis. Dasatinib is a 2-aminothiazole-derived inhibitor of Src family kinases, inhibits c-Abl and Bcr-Abl tyrosine kinase activity and shows efficacy against imatinib-resistant Bcr-Abl mutations. Combined treatment with bortezomib plus Dasatinib monohydrate caused cell cycle arrest in the G1 phase through inactivation of PDGFRβ and promoted bortezomib-induced apoptosis in GIST-T1 cells. Dasatinib monohydrate monotherapy demonstrates anti‑ovarian cancer activities. The effects of Dasatinib monohydrate and paclitaxel treatments on ovarian cancer cells appeared to be mediated by the Src pathway. |
CFN90169 | Pristimerin Pristimerin is a naturally occurring triterpenoid that has been shown to suppress the proliferation of various cancer cell lines at the concentration (IC50) range of 0.2-4 μM, including those of breast, glioma, prostate, pancreatic, ovarian, colon. Pristimerin exhibits inhibitory effects against diverse phytopathogenic fungi, it shows good preventive effect and curative effect against wheat powdery mildew in vivo. It has a wide spectrum of targets including ROS, IKK, NF-κB, Akt, mTOR, Bcr-Abl. |
CFN90172 | Gambogic acid Gambogic acid is a tissue-specific proteasome inhibitor, which has anticancer, anti-inflammatory, and anti-angiogenesis activities. Gambogic acid induces LRIG1 (leucine-rich repeat and Ig-like domain-containing-1) upregulation, which is responsible for EGFR (epidermal growth factor receptor) degradation and its downstream Akt/mTORC1 inhibition. |